RWEソリューション（リアルワールドエビデンスソリューション）の世界市場、2024-2031年

世界のRWEソリューション（リアルワールドエビデンスソリューション）市場は、予測期間（2024-2031年）にCAGR 12.40％で成長すると予測されます。同市場の成長は、医療業界が患者中心のアプローチを優先し、革新的な治療法への患者アクセスを迅速化するため、より迅速で効率的な臨床試験を目指していることに起因しています。例えば、ベラナ・ヘルス社は2023年6月、臨床試験施設の候補を特定するための定額制ツールVeraSiteを発表しました。このツールにより、スポンサーやCROは臨床の専門知識や患者集団を持つ診療所を迅速に特定し、治験実施施設の選定を支援したり、関心のある診療所と直接コンタクトを取ったりすることができます。

セグメント別の展望

オンコロジーサブセグメントが世界のRWEソリューション市場で大きなシェアを占めると予想される

アプリケーションの中でも、腫瘍学サブセグメントが世界のRWEソリューション市場でかなりのシェアを占めると予想されます。このセグメントの成長は、より広範な業界動向を反映して、がん研究と治療においてデータ主導の意思決定が重視されるようになっていることに起因しています。さらに、市場プレーヤーはソリューションの需要を満たすために新製品の発売を模索しています。.例えば、2023年5月、フラットアイアン・ヘルス社は、がん領域のリアルワールド・エビデンス創出に進出しました。同社のIntegrated real-world evidence（RWE）Solutionsのアプローチにより、パートナーは強力なRWEとインサイトを生成することができます。これにより、Flatironは製品ライフサイクル全体にわたるがん領域のRWD/E開発のための「ワンストップ・ショップ」となり、がん患者の体験を向上させることができます。

地域別展望

世界のRWEソリューション市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、世界のその他の地域（中東とアフリカ、中南米）を含む地域別にさらに細分化されます。このうち、アジア太平洋地域は、高齢者の増加、がんや慢性疾患の発生率の高さ、さらに医療サービスに対する需要の増加により、世界市場で突出したシェアを占めると予想されます。

世界のRWEソリューション市場は北米地域がCAGRで大きく成長する見込み

すべての地域の中で、北米地域は予測期間中にかなりのCAGRで成長すると予想されています。この地域の成長は、ウェアラブル、医療アプリ、電子カルテなどの高品質な実世界データソースの利用可能性が高まっていることに起因しています。.2023年10月のNational Institute og Health（gov.）によると、この出版物は、医療におけるリアルワールドエビデンス（RWE）を活用するための世界の規制状況の最新レビューを提供しています。異なる地域におけるフレームワーク、ガイダンス、データの質、調査方法、手続きガイダンスの利用可能性を評価しています。また、RWEの活用における規制当局や医療技術評価（HTA）機関間の整合性だけでなく、今後の開発や調和のためのギャップや潜在的な機会も強調しています。

2023年12月、BC PlatformsはMedexprimを買収し、世界なバイオファーマ・パートナーに実臨床および画像データ資産への安全なアクセスを提供する能力を拡大しました。

目次

第1章 レポート概要

• 業界の現状分析と成長ポテンシャルの展望
• 調査方法とツール
• 市場内訳
  • セグメント別
  • 地域別

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向
  • 主な調査結果
  • 推奨事項
  • 結論

第3章 競合情勢

• 主要企業分析
• Cegedim Health
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Clinigen Ltd.
  • 会社概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Cognizant Technology Solutions Corp.
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• 主要戦略分析

第4章 市場セグメンテーション

• RWEソリューションの世界市場：コンポーネント別
  • サービス
  • データセット
    • 個別データセット
    • 統合データセット
• RWEソリューションの世界市場：アプリケーション別
  • 医薬品開発・承認
  • 上市後調査
  • 市場アクセス償還/カバーエンドユーザー意思決定
  • 臨床・規制上の意思決定
• RWEソリューションの世界市場：エンドユーザー別
  • 製薬・医療機器企業
  • 医療プロバイダー
  • 医療ペイヤー
  • その他（患者・患者支援団体、研究機関、学術機関）

第5章 地域別分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 世界のその他の地域

第6章 企業プロファイル

• Dassault Systemes S.E.
• Flatiron Health
• IBM Corp.
• ICON plc.
• India Medtronic Pvt. Ltd.
• IQVIA, Inc.
• Optum, Inc.
• Oracle
• Parexel International Corp.
• PerkinElmer Inc.
• Real Endpoints
• Saama Technologies, LLC.
• SAS Institute Inc.
• Syneos Health
• Thermo Fisher Scientific Inc.
• TriNetX LLC

LIST OF TABLES

• 1.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
• 2.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 3.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY DATA SETS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 4.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
• 5.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 6.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN POST-MARKET SURVEILLANCE MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 7.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN ACCESS REIMBURSEMENT/COVER END USER DECISION MAKING MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 8.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN CLINICAL AND REGULATORY DECISION-MAKING MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 9.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
• 10.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 11.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR HEALTHCARE PROVIDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 12.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR HEALTHCARE PAYERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 13.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 14.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 15.NORTH AMERICAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
• 16.NORTH AMERICAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
• 17.NORTH AMERICAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
• 18.NORTH AMERICAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
• 19.EUROPEAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
• 20.EUROPEAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
• 21.EUROPEAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
• 22.EUROPEAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
• 23.ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
• 24.ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
• 25.ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
• 26.ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
• 27.REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 28.REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
• 29.REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
• 30.REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END USER, 2023-2031 ($ MILLION)

LIST OF FIGURES

• 1.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET SHARE BY COMPONENT, 2023 VS 2031 (%)
• 2.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY SERVICES MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 3.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY DATA SETS MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 4.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY DISPARATE DATA SETS MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 5.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY INTEGRATED DATA SETS MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 6.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET SHARE BY APPLICATION, 2023 VS 2031 (%)
• 7.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 8.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN ONCOLOGY MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 9.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN NEUROLOGY MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 10.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN IMMUNOLOGY MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 11.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN CARDIOVASCULAR DISEASE MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 12.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN OTHER THERAPEUTIC AREAS MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 13.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN MEDICAL DEVICE DEVELOPMENT AND APPROVALS MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 14.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN POST-MARKET SURVEILLANCE MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 15.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN MARKET ACCESS REIMBURSEMENT/COVERAGE DECISION MAKING MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 16.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN CLINICAL AND REGULATORY DECISION-MAKING MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 17. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET SHARE BY END-USER, 2023 VS 2031 (%)
• 18.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 19.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR HEALTHCARE PROVIDERS MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 20.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR HEALTHCARE PAYERS MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 21.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR OTHERS MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 22.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET SHARE BY REGION, 2023 VS 2031 (%)
• 23.US REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
• 24.CANADA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
• 25.UK REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
• 26.FRANCE REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
• 27.GERMANY REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
• 28.ITALY REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
• 29.SPAIN REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
• 30.REST OF EUROPE REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
• 31.INDIA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
• 32.CHINA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
• 33.JAPAN REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
• 34.SOUTH KOREA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
• 35.REST OF ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
• 36.LATIN AMERICA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
• 37.THE MIDDLE EAST & AFRICA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)

Global Real World Evidence Solutions Market Size, Share & Trends Analysis Report by Component (Services, and Data Sets), by Application (Drug Development and Approvals, Post-Market Surveillance, Market Access Reimbursement/Cover End-User Decision Making, and Clinical and Regulatory Decision-Making), and by End-User (Pharmaceutical & Medical Device Companies, Healthcare Providers, Healthcare Payers, and Others ) Forecast Period (2024-2031)

The global real-world evidence solutions market is anticipated to grow at a CAGR of 12.40% during the forecast period (2024-2031). The market's growth is attributed to the growing demand for healthcare industry is prioritizing patient-centric approaches, aiming for faster and more efficient clinical trials to expedite access to innovative treatments for patients.. For instance, in June 2023, Verana Health launched VeraSite, a subscription-based tool for identifying potential clinical trial sites. The tool allows sponsors and CROs to quickly identify practices with clinical expertise and patient populations, guiding site selection and allowing direct contact with practices of interest.

Segmental Outlook

The global real-world evidence solutions market is segmented by component, application, and end user. Based on the component, the market is sub-segmented into services, and data sets.. Based on the application, the market is sub-segmented intodrug development and approvals, post-market surveillance, market access reimbursement/cover end-user decision making, and clinical and regulatory decision-making.. Furthermore, based on end users, the market is sub-segmented into pharmaceutical & medical device companies, healthcare providers, healthcare payers, and others.. The pharmaceutical and medical device companies' subcategory is expected to capture a significant portion of the market share within the end-user segment. The growth can be attributed to the increasing importance of real world evidence (RWE) studies are increasingly crucial in drug approval, real-world performance assessment, and preventing recalls, aiding in patient benefit identification, regulatory approvals, reimbursement, and increased indications of use.

Oncology Sub-Sub-Segment is Anticipated to Hold a Considerable Share of the Global Real-World Evidence Solutions Market

Among the applications, the oncology sub-sub-segment is expected to hold a considerable share of the global real-world evidence solutions market. The segmental growth is attributed to the growing emphasis for data-driven decision-making in cancer research and treatment, reflecting wider industry trends. Furthermore, the market players are looking for the new product launch to meet the demand for the solutions. . For instance, in May 2023, Flatiron Health expanded into oncology real-world evidence generation. Its Integrated real-world evidence (RWE) Solutions approach allows partners to generate strong RWE and insights. It enables Flatiron to become a 'one-stop-shop' for oncology RWD/E development across the product lifecycle, hence enhancing cancer patient experiences.

Regional Outlook

The global real-world evidence solutions market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the growing number of elderly individuals and the higher occurrence of cancer and chronic illnesses in the region, additionally there has been an increase in demand for healthcare services..

The North American region is Expected to Grow at a Significant CAGR in the global Real-World Evidence Solutions Market

Among all regions, the North American region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the growing availability of high-quality real-world data sources such as wearables, healthcare apps, and electronic health records. . According to the National Institute og Health (gov.), in October 2023, the publication provides an updated review of the global regulatory landscape for leveraging real-world evidence (RWE) in healthcare. It evaluates the availability of frameworks, guidance, data quality, study methods, and procedural guidance in different regions. The review also highlights gaps and potential opportunities for future development and harmonization, as well as the alignment among regulators and health technology assessment (HTA) bodies in utilizing RWE..

Market Players Outlook

The major companies serving the global real-world evidence solutions market include Dassault Systemes S.E., IBM Corp., Oracle, PerkinElmer Inc., Thermo Fisher Scientific Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in August 2023, Thermo Fisher Scientific Inc. acquired CorEvitas, LLC, focusing on real-world evidence collection and use in routine clinical care, a high-growth market segment for pharmaceutical and biotechnology customers.

In December 2023, BC Platforms acquired Medexprim, expanding its capability to offer global biopharma partners secure access to real-world clinical and imaging data assets.

The Report Covers:

• Market value data analysis of 2023 and forecast to 2031.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global real-world evidence solutions market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies. Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1.Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1.Research Methods and Tools
• 1.2.Market Breakdown
  • 1.2.1.By Segments
  • 1.2.2.By Region

2.Market Overview and Insights

• 2.1.Scope of the Report
• 2.2.Analyst Insight & Current Market Trends
  • 2.2.1.Key Findings
  • 2.2.2.Recommendations
  • 2.2.3.Conclusion

3.Competitive Landscape

• 3.1.Key Company Analysis
• 3.2.Cegedim Health
  • 3.2.1.Overview
  • 3.2.2.Financial Analysis
  • 3.2.3.SWOT Analysis
  • 3.2.4.Recent Developments
• 3.3.Clinigen Ltd.
  • 3.3.1.Overview
  • 3.3.2.Financial Analysis
  • 3.3.3.SWOT Analysis
  • 3.3.4.Recent Developments
• 3.4.Cognizant Technology Solutions Corp.
  • 3.4.1.Overview
  • 3.4.2.Financial Analysis
  • 3.4.3.SWOT Analysis
  • 3.4.4.Recent Developments
• 3.5.Key Strategy Analysis

4.Market Segmentation

• 4.1.Global Real-World Evidence Solutions Market by Component
  • 4.1.1.Services
  • 4.1.2.Data Sets
    • 4.1.2.1.Disparate Data Sets
    • 4.1.2.2.Integrated Data Sets
• 4.2.Global Real-World Evidence Solutions Market by Application
  • 4.2.1.Drug Development and Approvals
  • 4.2.2.Post-Market Surveillance
  • 4.2.3.Market Access Reimbursement/Cover End-User Decision Making
  • 4.2.4.Clinical and Regulatory Decision-Making
• 4.3.Global Real-World Evidence Solutions Market by End-User
  • 4.3.1.Pharmaceutical & Medical Device Companies
  • 4.3.2.Healthcare Providers
  • 4.3.3.Healthcare Payers
  • 4.3.4.Others (Patients and Patient Advocacy Groups, Research Organizations and Academia)

5.Regional Analysis

• 5.1.North America
  • 5.1.1.United States
  • 5.1.2.Canada
• 5.2.Europe
  • 5.2.1.UK
  • 5.2.2.Germany
  • 5.2.3.Italy
  • 5.2.4.Spain
  • 5.2.5.France
  • 5.2.6.Rest of Europe
• 5.3.Asia-Pacific
  • 5.3.1.China
  • 5.3.2.India
  • 5.3.3.Japan
  • 5.3.4.South Korea
  • 5.3.5.Rest of Asia-Pacific
• 5.4.Rest of the World

6.Company Profiles

• 6.1.Dassault Systemes S.E.
• 6.2.Flatiron Health
• 6.3.IBM Corp.
• 6.4.ICON plc.
• 6.5.India Medtronic Pvt. Ltd.
• 6.6.IQVIA, Inc.
• 6.7.Optum, Inc.
• 6.8.Oracle
• 6.9.Parexel International Corp.
• 6.10.PerkinElmer Inc.
• 6.11.Real Endpoints
• 6.12.Saama Technologies, LLC.
• 6.13.SAS Institute Inc.
• 6.14.Syneos Health
• 6.15.Thermo Fisher Scientific Inc.
• 6.16.TriNetX LLC